Micellar Glutathione Outperforms Standard Forms in Human Study

A human pilot study reports that a novel micellar glutathione formulation (LipoMicel®, LMG) delivers significantly higher oral bioavailability compared to standard and liposomal glutathione forms. In a randomized, double-blind crossover trial (n=14), LMG at a lower dose (300 mg) achieved ~2.5-fold greater systemic exposure and peak GSH levels versus standard glutathione (500 mg), with up to 4-fold higher exposure when dose-normalized. The formulation also improved the GSH/GSSG ratio, indicating a more favorable redox balance, while maintaining similar metabolite profiles overall except for a notable increase in methionine exposure. In a 30-day follow-up, daily LMG supplementation (600 mg/day) was well tolerated with no significant changes in clinical safety markers. These findings position micellar glutathione as a promising strategy for enhancing oral GSH delivery, warranting further long-term clinical evaluation.

Source : https://www.mdpi.com/2076-3921/15/3/354